GlassScriptPhysician profile
Donald N Tsynman
NPI 1508028143
$7,457.35
in general payments reported to CMS, 2019-2025
31 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $485 · 2021: $1,397 · 2022: $1,497 · 2023: $1,419 · 2024: $1,285 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,955 · Education: $15.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.70 |
| Education | $15.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,818.30 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $589.09 | 2019-2025 | Entyvio, Gattex, Fosrenol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $572.86 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $446.99 | 2020-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $437.77 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $280.06 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $263.10 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $248.66 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $226.57 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $210.66 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $183.64 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $176.72 | 2022-2025 | Dupixent |
| Pfizer INC. | $143.34 | 2021-2025 | |
| Ardelyx, INC. | $128.25 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $95.19 | 2020-2023 | Ocaliva |
| Celgene Corporation | $84.12 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $60.29 | 2019-2022 | |
| Amgen INC. | $50.48 | 2022-2023 | Amjevita |
| Qol Medical, LLC | $41.84 | 2021-2024 | Sucraid |
| Allergan, INC. | $39.59 | 2019-2020 | |
| Lilly USA, LLC | $38.65 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $34.08 | 2024 | Bylvay, Iqirvo |
| Alnylam Pharmaceuticals INC. | $27.16 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $25.48 | 2022-2023 | Dat Closure Device |
| Fresenius Kabi USA, LLC | $20.89 | 2023 | Idacio |
| Braintree Laboratories, INC. | $20.56 | 2020 | |
| Mauna Kea Technologies, INC. | $19.96 | 2021 | |
| Novo Nordisk INC | $19.43 | 2025 | Wegovy |
| Celltrion USA INC. | $15.71 | 2024 | Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.91 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Tsynman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.